Laia Gomez-Muñoz, David Perna-Barrull, Paula Sol Ventura, Aina Valls, Francesca Castiello, Marta Vives-Pi, Marta Murillo-Vallés
{"title":"儿童1型糖尿病患者外周血内皮型与年龄相关的鉴定","authors":"Laia Gomez-Muñoz, David Perna-Barrull, Paula Sol Ventura, Aina Valls, Francesca Castiello, Marta Vives-Pi, Marta Murillo-Vallés","doi":"10.1155/pedi/5512196","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aims:</b> This study aimed to identify age-related peripheral immune endotypes in pediatric patients with type 1 diabetes (T1D) at disease onset and assess their metabolic control 1 year post-diagnosis. <b>Methods:</b> Immune cell subpopulations (T and B lymphocytes, myeloid cells, and natural killer [NK] cells) were analyzed via multicolor flow cytometry in pediatric T1D patients and age- and sex-matched controls, grouped as <7 years, 7-12 years, and >12 years. Sociodemographic, clinical, and metabolic data were collected, including autoantibodies, bicarbonate (HCO<sub>3</sub>), C-peptide, HbA1c, and time in range (TIR), with follow-up for 1 year to evaluate partial remission (PR) likelihood and metabolic control. <b>Results:</b> Patients <7 years showed reduced regulatory immune cells (memory/activated regulatory T lymphocytes (Tregs), regulatory B cells, and Th17) and more severe disease onset (shorter symptoms, greater acidosis, and lower C-peptide). Ages 7-12 exhibited increased memory B cells, particularly the unswitched ones. Myeloid cells showed no significant variation in T1D, despite age trends in controls. Anti-insulinoma-antigen 2 (IA2) titers were lower in patients >12 years, while anti-glutamic acid decarboxylase 65 (GAD65) positivity remained constant. Younger patients had lower PR rates and poorer glycemic control at 1 year. <b>Conclusions:</b> Younger patients face greater immune dysregulation and β-cell loss, while older patients show better immune maturity and metabolic outcomes. These differences underline the need for age-specific T1D therapies.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"5512196"},"PeriodicalIF":5.6000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12496154/pdf/","citationCount":"0","resultStr":"{\"title\":\"Identification of Peripheral Blood Endotypes Associated With Age in Pediatric Type 1 Diabetes.\",\"authors\":\"Laia Gomez-Muñoz, David Perna-Barrull, Paula Sol Ventura, Aina Valls, Francesca Castiello, Marta Vives-Pi, Marta Murillo-Vallés\",\"doi\":\"10.1155/pedi/5512196\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aims:</b> This study aimed to identify age-related peripheral immune endotypes in pediatric patients with type 1 diabetes (T1D) at disease onset and assess their metabolic control 1 year post-diagnosis. <b>Methods:</b> Immune cell subpopulations (T and B lymphocytes, myeloid cells, and natural killer [NK] cells) were analyzed via multicolor flow cytometry in pediatric T1D patients and age- and sex-matched controls, grouped as <7 years, 7-12 years, and >12 years. Sociodemographic, clinical, and metabolic data were collected, including autoantibodies, bicarbonate (HCO<sub>3</sub>), C-peptide, HbA1c, and time in range (TIR), with follow-up for 1 year to evaluate partial remission (PR) likelihood and metabolic control. <b>Results:</b> Patients <7 years showed reduced regulatory immune cells (memory/activated regulatory T lymphocytes (Tregs), regulatory B cells, and Th17) and more severe disease onset (shorter symptoms, greater acidosis, and lower C-peptide). Ages 7-12 exhibited increased memory B cells, particularly the unswitched ones. Myeloid cells showed no significant variation in T1D, despite age trends in controls. Anti-insulinoma-antigen 2 (IA2) titers were lower in patients >12 years, while anti-glutamic acid decarboxylase 65 (GAD65) positivity remained constant. Younger patients had lower PR rates and poorer glycemic control at 1 year. <b>Conclusions:</b> Younger patients face greater immune dysregulation and β-cell loss, while older patients show better immune maturity and metabolic outcomes. These differences underline the need for age-specific T1D therapies.</p>\",\"PeriodicalId\":19797,\"journal\":{\"name\":\"Pediatric Diabetes\",\"volume\":\"2025 \",\"pages\":\"5512196\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12496154/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/pedi/5512196\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/pedi/5512196","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Identification of Peripheral Blood Endotypes Associated With Age in Pediatric Type 1 Diabetes.
Aims: This study aimed to identify age-related peripheral immune endotypes in pediatric patients with type 1 diabetes (T1D) at disease onset and assess their metabolic control 1 year post-diagnosis. Methods: Immune cell subpopulations (T and B lymphocytes, myeloid cells, and natural killer [NK] cells) were analyzed via multicolor flow cytometry in pediatric T1D patients and age- and sex-matched controls, grouped as <7 years, 7-12 years, and >12 years. Sociodemographic, clinical, and metabolic data were collected, including autoantibodies, bicarbonate (HCO3), C-peptide, HbA1c, and time in range (TIR), with follow-up for 1 year to evaluate partial remission (PR) likelihood and metabolic control. Results: Patients <7 years showed reduced regulatory immune cells (memory/activated regulatory T lymphocytes (Tregs), regulatory B cells, and Th17) and more severe disease onset (shorter symptoms, greater acidosis, and lower C-peptide). Ages 7-12 exhibited increased memory B cells, particularly the unswitched ones. Myeloid cells showed no significant variation in T1D, despite age trends in controls. Anti-insulinoma-antigen 2 (IA2) titers were lower in patients >12 years, while anti-glutamic acid decarboxylase 65 (GAD65) positivity remained constant. Younger patients had lower PR rates and poorer glycemic control at 1 year. Conclusions: Younger patients face greater immune dysregulation and β-cell loss, while older patients show better immune maturity and metabolic outcomes. These differences underline the need for age-specific T1D therapies.
期刊介绍:
Pediatric Diabetes is a bi-monthly journal devoted to disseminating new knowledge relating to the epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes in childhood and adolescence. The aim of the journal is to become the leading vehicle for international dissemination of research and practice relating to diabetes in youth. Papers are considered for publication based on the rigor of scientific approach, novelty, and importance for understanding mechanisms involved in the epidemiology and etiology of this disease, especially its molecular, biochemical and physiological aspects. Work relating to the clinical presentation, course, management and outcome of diabetes, including its physical and emotional sequelae, is considered. In vitro studies using animal or human tissues, whole animal and clinical studies in humans are also considered. The journal reviews full-length papers, preliminary communications with important new information, clinical reports, and reviews of major topics. Invited editorials, commentaries, and perspectives are a regular feature. The editors, based in the USA, Europe, and Australasia, maintain regular communications to assure rapid turnaround time of submitted manuscripts.